Paloma Diaz‐Fernandez

Paloma Diaz‐Fernandez

Auto-generated profile, based on publicly available information

Paloma Diaz‐Fernandez

Biopharm Process Research, Biopharm Product Development and Supply GlaxoSmithKline R&D Stevenage UK

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2020 in Biotechnology Progress
Verified
Journal Article
Closed access
PDF file
RRRuth C. Rowland‐Jones
Ruth C. Rowland‐Jones
AGAlexander Graf
Alexander Graf
AWAngus Woodhams
Angus Woodhams
PDPaloma Diaz‐Fernandez
Paloma Diaz‐Fernandez
SWSteve Warr
Steve Warr
MHMarek Hoehse
Marek Hoehse

14 April 2022 in Metabolic Engineering
Verified
Journal Article
Closed access
GBGianmarco Barberi
Gianmarco Barberi
ABAntonio Benedetti
Antonio Benedetti
PDPaloma Diaz-Fernandez
Paloma Diaz-Fernandez
DSDaniel C. Sévin
Daniel C. Sévin
JVJohanna Vappiani
Johanna Vappiani
Pierantonio FaccoPierantonio Facco
Pierantonio Facco

9 October 2024 in AIChE Journal
Verified
Journal Article
Open access
GBGianmarco Barberi
Gianmarco Barberi
ABAntonio Benedetti
Antonio Benedetti
PDPaloma Diaz‐Fernandez
Paloma Diaz‐Fernandez
DSDaniel C. Sévin
Daniel C. Sévin
JVJohanna Vappiani
Johanna Vappiani
Pierantonio FaccoPierantonio Facco
Pierantonio Facco
The identification of highly productive cell lines is crucial in the development of bioprocesses for the production of therapeutic monoclonal antibodies (mAbs). Metabolomics data provide valuable information for cell line selection and allow the study of the relationship with mAb productivity and product quality attributes. We propose a novel robust machine learning procedure which, exploiting dynamic metabolomic data from the Ambr®15 scale, supports the selection of highly productive cell lines during biopharmaceutical bioprocess development and scale‐up. The metabolomic profiles dynamics allows to identify the cell lines with high productivity, already in the early stages of experimentation, and the biomarkers that are the most related to mAb productivity, finding at the same time the key metabolic pathways for discriminating mAb productivity. Specifically, tricarboxylic acid cycle pathways are predominant in the early stages of the cultivation, while amino and nucleotide sugar pathways influence in the late stages of the culture.